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Quinine-containing beverages may cause health problems 
 
Updated BfR Health Assessment* No 020/2008, 17 February 2005 
 
Quinine is a bitter-tasting, crystalline white powder. It is obtained from the bark of the 
cinchona tree and belongs to the group of alkaloids. In medicine quinine is used to treat 
malaria and nocturnal leg cramps. In the food sector, quinine is used as a flavouring mainly 
in beverages like bitter lemon and tonic water. 
 
When larger amounts of quinine are consumed, it can constitute a health problem for some 
consumer groups. BfR sees risks in particular for quinine intakes during pregnancy. For 
instance, a newborn baby, whose mother had drunk more than 1 litre tonic water a day in the 
weeks up to its birth, suffered health disorders. Based on existing regulations in the 
medicinal product sector, BfR, therefore, advises pregnant women against drinking quinine-
containing beverages on precautionary grounds. People who have been advised against 
taking quinine, cinchona bark or their preparations by their doctors because of their clinical 
pictures should not consume any quinine-containing soft drinks either. This applies, for 
instance, to people who suffer from tinnitus, pre-existing damage to the optic nerve, 
haemolytic anaemia or who are hypersensitive to quinine or cinchona alkaloids. Patients with 
cardiac arrhythmia and people who take medicine that interacts with quinine, should only 
drink quinine-containing soft drinks after consulting their doctors. This applies in particular to 
medications which inhibit blood coagulation. At higher levels of tonic water consumption, it 
may be necessary to reduce their therapeutic dose. 
 
Already today quinine must be mentioned by name in the list of ingredients of quinine-
containing products. BfR also believes that there is a need for information which attracts the 
attention more particularly of pregnant women and other risk groups to possible health 
impairments. Motor vehicle drivers should be informed that larger amounts of quinine-
containing bitter beverages can cause visual disturbances. BfR recommends raising 
awareness about the possible health risks from quinine to consumers. Specific information 
should be provided about the symptoms of quinine hypersensitivity and cinchonism (typical 
adverse reactions to quinine). Consumers should be advised to immediately stop their 
quinine intake if these symptoms occur, and to consult a doctor. 
 
BfR recommends that the health assessment of quinine by the Scientific Committee on Food 
from 1988 should be updated.  
 
BfR is of the opinion that the problems of quinine-containing bitter soft drinks underline the 
importance of the systematic recording of adverse reactions that occur in conjunction with 
the consumption of foods. The Institute, therefore, explicitly supports the setting up of a 
central reporting office. 
 
1   Subject matter of the assessment 
 
BfR was asked to undertake the health assessment of quinine-containing beverages. The 
major objective was to clarify whether there is any scientific evidence of a possible 
association between the consumption of quinine-containing beverages and the isolated 
occurrence of health disorders in pregnant women and their newborn babies. The more 
recent reasons consist in the possible link between the consumption of quinine-containing 
beverages during pregnancy and the occurrence of health disorders in the mother and child. 
Furthermore, it was to be clarified whether, in addition to the prescribed labelling, a warning 
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for specific groups of persons (e.g. pregnant women) should also be prescribed for quinine-
containing beverages. Against this backdrop reference is made to the second recital in 
Directive 2002/67/EC on the labelling of foodstuffs containing quinine and of foodstuffs 
containing caffeine:  “According to the conclusions of the Scientific Committee on Food, there 
is no objection from the point of view of toxicology to the continued use of quinine at a certain 
maximum level in bitter drinks. However, consumption of quinine may be counter-indicated 
for certain people for medical reasons or because they are hypersensitive to the substance.” 
 
2   Results 
 
Although in the current case BfR was unable to identify any association after careful 
examination, the Institute recommends – on the basis of the currently available data and in 
line with the existing contraindication for quinine-containing medicinal products – to abstain 
from quinine-containing beverages during pregnancy. Along the lines of preventive health 
protection this recommendation reflects the numerous gaps in knowledge and the low safety 
margins between exposure doses and NOAEL (no observed adverse effect level) or between 
toxic doses and pharmacological effective doses. Furthermore, this recommendation upholds 
the principle that health protection in the food sector should at least be on a par with risk 
reduction measures in the medicinal product sector whereby pregnant women, unborn 
babies and infants are to be deemed to be groups requiring special protection. 
 
Besides pregnant women, other groups of individuals for which there is a contraindication in 
the medicinal product sector (for taking quinine to treat nocturnal calf muscle cramps or for 
taking cinchona bark and its preparations) should also refrain from drinking quinine-
containing soft beverages. These are people who suffer from tinnitus or pre-existing damage 
to the optic nerve, glucose-6-phosphate-dehydrogenase deficiency (symptoms: haemolytic 
anaemia), myasthenia gravis or hypersensitivity to quinine or cinchona alkaloids. Individuals 
suffering from cardiac arrhythmia or who are taking medicines that interact with quinine, 
should only consume quinine-containing soft drinks after consulting their doctor. This applies 
in particular to anticoagulant medication as there have been reports of cases in which the 
dose of anticoagulant preparations had to be reduced following higher consumption of tonic 
water. For motor vehicle drivers, the mention of possible visual disturbances after consuming 
larger amounts of bitter beverages is relevant. 
 
BfR believes that measures are needed to adequately inform the risk groups concerned. 
Furthermore, BfR recommends explaining the symptoms of cinchonism and quinine 
hypersensitivity to consumers and advising them to stop their quinine intake immediately and 
to immediately consult a doctor when these symptoms occur. BfR recommends that the 1988 
assessment of the Scientific Committee on Food should be updated and in this context 
efforts should be made to establish a coordinated consumer information within the EU. 
 
3   Reasons 
 
3.1   Risk assessment 
 
3.1.1   Agent 
 
Besides its isomer quinidine, quinine (6-methoxycinchonan-9-ol, CAS No. 130-95-0) is the 
most important principal alkaloid of cinchona bark (Cinchonae cortex), the dried bark of 
Cinchona pubescens, Vahl (synonyms: Cinchona succirubra, Pavon; family: Rubiaceae). The 
salts of quinine are mainly used in medicinal products. Furthermore, because of its 
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characteristic bitter flavour, it is used in foods, particularly in soft drinks (e.g. tonics, bitter 
lemon drinks). 
 
3.1.1.1 Food law provisions 
 
According to Directive 2002/67/EC of the Commission of 18 July 2002 on the labelling of 
foodstuffs containing quinine, and of foodstuffs containing caffeine and/or the corresponding 
provisions of the Food Labelling Ordinance of 15 December 1999 (last amended on 16 
January 2004) quinine and its salts, which are used as flavourings in the production or 
preparation of a foodstuff, must be mentioned by name in the list of ingredients immediately 
after the term “Flavouring”. 
 
The Council Directive of 22 June 1988 (88/388/EEC) on flavourings for use in foods does not 
set any maximum levels for quinine or its salts. In consequence there are separate national 
provisions. The latest version of the German Flavourings Ordinance of 22 December 1981 
(Annexes 4 and 5) gives for quinine, quinine hydrochloride and quinine sulphate the following 
maximum levels in ready-to-eat foods, calculated as quinine: total 300 mg/kg in spirits and 
85 mg/kg in non-alcoholic beverages. Other beverages or foods may not contain quinine as a 
flavouring pursuant to Annex 4 to the Flavourings Ordinance. Furthermore, §5 of the 
Flavourings Ordinance stipulates the inclusion of the wording “contains quinine” in the 
labelling of flavourings which contain quinine or its salts. 
 
3.1.2 Hazard potential and exposure 
 
Most knowledge about the action profile of quinine derives from its pharmaceutical use. 
Hence, an overview is first given of the spectrum of pharmacologically and toxicologically 
relevant effects and related aspects described in the relevant literature; attention also 
focuses on dose relations. Section 3.1.2.2 deals with the opinions of international bodies on 
the risk assessment of quinine use in foods. This assessment is based on literature searches 
on the current topic in the DIMDI database xtoxlitall. 
 
3.1.2.1 Quinine in medicine 
 
3.1.2.1.1 Current uses 
 
Malaria treatment 
Quinine has been used as a pure substance since 1820 to treat malaria and fever attacks. 
The development of synthetic malaria medicines led to the almost complete abandoning of 
this application. However, since the middle of the previous century it has been once again 
growing in importance as a consequence of the appearance of chloroquine-resistant strains 
of Plasmodium falciparum (1, 2). The malaria treatment lasts between 1½ - 2 weeks with oral 
administration of quinine salts at doses which correspond to at least 0.8 – 1g free quinine 
base (molecular weight: 324.4) per day (e.g. daily dose of 1 – 1.25 g quinine hydrochloride 
dihydrate) (molecular weight:  396.9) or 1.95 g quinine sulphate dihydrate (molecular weight:  
783) (1-6). 
 
Peripheral muscle relaxant 
Single oral doses of 200 mg quinine sulphate dihydrate a day, equivalent to 166 mg free 
quinine base, are applied in the treatment for nocturnal leg cramps. If necessary, the dose 
can be doubled (2, 3). 
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In the USA the Food and Drug Administration (FDA) advised against the use of quinine 
sulphate products to treat nocturnal calf muscle cramps because of the unfavourable risk-
benefit ratio particularly for older patients (9). 
 
A meta-analysis of the efficacy of quinine or quinine salts to treat nocturnal leg cramps in 
older people revealed that quinine sulphate reduced the number of muscular cramps 
compared with the placebo. According to the authors, the study results point to accumulation 
in conjunction with repeated doses which means that treatment lasting at least four weeks 
may be necessary in order to achieve the desired effect (35). 
 
There is no known threshold dose upwards of which the muscle relaxing effect occurs. 
 
 
3.1.2.1.2 Pharmacodynamics 
 
Quinine destroys erythrocytic schizonts (dividing stage of the protozoan in red blood cells) in 
all forms of malaria in humans. Discussions focus on whether the mechanism is based on 
intercalation. The quinine molecule intercalates itself between the bases of the parasite DNA 
and inhibits nucleic acid synthesis (5, 6). Vis a vis other unicellular  organisms (e.g. bacteria, 
yeast) and spermatozoa, quinine also manifests a more or less destructive effect (6). Some 
of the areas of use outlined above refer to the analgesic (pain-relieving), antipyretic (fever-
reducing), local anaesthetic and muscle-relaxing effects of quinine. The muscle-relaxing 
effect is based on the antagonistic action to physostigmine on the skeletal muscles as also 
exhibited by curare. The excitability of the motor end plate is reduced by quinine and 
reactions to repeated nervous stimuli and acetylcholine are reduced by quinine (2, 5, 6). On 
the gravid uterus quinine has a slightly oxytocic effect. In the past quinine was, therefore, 
used in the induction phase of birth at an oral dose of between 300 and 500 mg twice daily in 
order to induce labour although this effect has not been verified (7). It is no longer 
administered for this purpose. There are numerous case reports of the ingestion of high 
doses of quinine (mostly several grams) to self-induce abortion (cf. 3.1.2.1.6). 
 
3.1.2.1.3 Pharmacokinetics 
 
After oral administration quinine is almost completely absorbed. Maximum blood levels are 
achieved after 1 to 3 hours. Values of between 70-90% and of 4 to 12 hours for plasma half-
life are given for plasma protein binding. In the erythrocytes of healthy individuals, the 
quinine level is 3 to 5 times and in parasitised erythrocytes 20 up to 100 times higher than in 
plasma. In the other organs distribution is largely even. In the cerebral spinal fluid (CSF), 
however, only 7% of the serum values are reached at the same time. Quinine crosses the 
placenta barrier and quickly reaches foetal tissue. On the basis of older studies it was 
presumed that maternal reabsorption of quinine from the foetus is slow and excretion in 
foetal urine is limited so that quinine may accumulate in foetal tissue (36, 37). Quinine can be 
detected in human milk. It is subject to high metabolism in the liver and 95% is excreted as 
metabolites and 5% in unchanged form in urine. There are some reports that even after 
treatment spanning several days, there was no accumulation (2, 6). In the case of an acidic 
urine pH, excretion is accelerated, and slowed down in the case of an alkaline pH. The latter 
can also lead to elevated quinine plasma concentrations and may reinforce possible toxic 
effects (1, 2, 5, 6, 9). 
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3.1.2.1.4 Adverse reactions 
 
Concerning the use of quinine-containing medicines to treat malaria or nocturnal leg cramps, 
adverse effects are mentioned which occur relatively frequently in the therapeutic dose range 
in conjunction with long term or repeated administration (manifestations: CNS, 
gastrointestinal tract, skin). They are classed together as cinchonism. The current  
Rote Liste ® mentions the following adverse reactions (3): 
 
? Neurotoxic effects (e.g. headache, tinnitus, visual disturbances, confusion) 
? Gastrointestinal disorders (e.g. nausea, vomiting, diarrhoea) 
? Exanthema (cf. h) 
? Cardiac stimulus conduction disorders 
? Fall in blood pressure (at high doses) 
? Kidney damage (rare) 
? Haematological disorders (cf. h) (e.g. haemolytic anaemia, leucopenia, thrombopenia, 
hypoprothrombinaemia) 
? Hypersensitivity reactions (e.g. skin reactions, drug fever, bronchospasms, changes 
in blood count, liver disorders, isolated cases of disseminated intravasal coagulation). 
 
International publications point out that cinchonism involving auditory and visual disturbances 
may already occur after low quinine doses (9) in individuals who are hypersensitive to 
quinine and that ototoxic and oculotoxic symptoms are included amongst the set of 
symptoms of quinine hypersensitivity (2). Of the hypersensitivity-related changes in blood 
count, medical literature focuses – apart from the thrombocytopenic purpura (see 3.1.2.3.2) 
caused by small quinine intakes from bitter beverages – on blackwater fever. It has been 
observed as a rare hypersensitivity reaction to quinine intake during pregnancy and malaria 
treatment (2, 6, 9) (cf. also 3.1.2.1.6). The trio of massive haemolysis, haemoglobinaemia 
and haemoglobinuria are described as “blackwater fever”. It can lead to anuria, kidney failure 
and even death. It is presumed that in these cases as well as in milder forms of quinine-
related haemolysis, the main individuals affected are those with a genetic glucose-6-
phosphate-dehydrogenase deficiency (1, 2, 6, 9). Given the importance of this problem for 
the food sector, the former Federal Institute for Consumer Health Protection and Veterinary 
Medicine, BgVV, had already recommended in 2000 that SCF should examine the possibility 
of warnings. 
 
Finally, one adverse quinine reaction which is not mentioned in the Rote Liste ® , that occurs 
both during the treatment of malaria and leg cramps, is the induction of hyperinsulinaemia 
and hypoglycaemia by stimulating beta cells of the Islets of Langerhans described in the 
literature. This can cause serious complications particularly during pregnancy (2, 9, 11). 
 
3.1.2.1.5 Contraindications and precautions 
 
The Rote Liste ® indicates pregnancy as a contraindication for the quinine doses used to 
treat both malaria and nocturnal leg cramps. The reasons given are oxytocic action and 
embryotoxicity at high doses (eye defects and deafness). The contraindications mentioned 
are tinnitus, prior damage to the optic nerve, glucose-6-phosphate-dehydrogenase deficiency 
(symptoms: haemolytic anaemia) and myasthenia gravis. In patients suffering from cardiac 
arrhythmia a precautious dosage is recommended (3). 
 
The pharmacological standard literature also mentions quinine hypersensitivity (1, 5, 6, 9), 
kidney and liver damage (1) as well as lactation (6) as contraindications (2, 5, 6, 9). 
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In the case of pregnant women suffering from life-threatening malaria, a risk-benefit analysis 
may conclude that treatment with quinine may be necessary under certain circumstances (9). 
The American Academy of Paediatrics (9) is of the opinion that quinine treatment can 
probably be tolerated during lactation. 
 
3.1.2.1.6 Administration of therapeutic doses of quinine during pregnancy, misuse of quinine 
as an abortifacient 
 
Publications on the adverse, toxic effects of quinine on the maternal organism or the foetus 
mostly refer to quinine intakes as an abortifacient and less frequently to therapeutic 
applications. 
 
In the older literature there are reports on the pharmaceutic application of quinine to promote 
contractions during the induction phase of birth (cf. 3.1.2.1.2) and for the purpose of abortion 
in the case of foetal death in uteri whereby the oxytocic effect of quinine is described as 
uncertain (7, 8). Older studies on the use of quinine for the induction of labour showed that, 
besides the already mentioned possible quinine accumulation in foetal tissue, quinine 
treatment probably as a consequence of intrauterine respiratory depression (asphyxia) 
frequently led to meconium being excreted into the amniotic fluid (36, 37). More rarely an 
inadequate involution of the uterus was registered (37). The conclusions by King (37) that the 
induction of labour with quinine sulphate (repeated administration of 0.65 g, corresponding to 
0.54 g quinine base) had led to the death of the foetus in several cases, was contradicted by 
the data in the two other studies (36, 38). 
 
Concerning the treatment of severe forms of malaria during pregnancy, current literature 
points out that there are no indications that quinine may have an oxytocin-like effect in the 
third trimester of pregnancy (9). However this somewhat contradicts the findings by 
Looareesuwan et al. (11). The latter had examined the side-effects of quinine treatment in 
the last trimester of pregnancy in 12 patients suffering from severe falciparum malaria. The 
patients were given an initial dose of 10 or 20 mg quinine hydrochloride (equivalent to 8.3 
and 16.7 mg quinine base) per kg bodyweight intravenously over a period of 4 hours, 
followed by 10 mg quinine dihydrochloride/kg bodyweight intravenously every 8 hours. Once 
they were able to swallow, treatment was continued with quinine sulphate tablets (no 
indication of dose) so that the total administration duration was 7 days. Uterus activity 
increased in the course of treatment in two cases, whereby in one patient the frequency 
increased and in the other, the amplitude of the uterus contractions. The labour pains had 
not started in either of the two women; in both cases malaria must also be considered as the 
factor that triggered contractions apart from quinine. Out of the three patients who were in 
labour, two gave birth normally whereas the third had a Caesarean section because of 
intrauterine hypoxia of the foetus. 7 out of 12 patients developed hypoglycaemia and 
hyperinsulinaemia; in only two of the above mentioned cases did the patients already suffer 
from these conditions prior to the administration of quinine. The authors come to the 
conclusion that in the last trimester of pregnancy, it is not the oxytocin-like effect of quinine 
but rather its ability to induce the release of insulin which is to be regarded as its most 
important toxic effect (cf. also 3.1.2.1.4). 
 
In older articles various cases were compiled in which maternal as well as foetal toxicity 
effects were described following the abusive ingestion of quinine as an abortifacient. 
However, frequently no further information is available like e.g. on the use of other abortion 
agents (8, 12-14). Dannenberg et al. (8) identified e.g.  70 cases in which quinine was 
administered to terminate a known or suspected pregnancy. At least 11 of them (16%) led to 
death of the mother, in at least 41 cases (59%) the offspring manifested congenital 
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anomalies for which quinine was thought to be the cause. Only in 3 cases (4%) did abortion 
take place without maternal death. Acute kidney failure and acute haemolytic anaemia were 
the main causes of the maternal fatalities (cf. 3.1.2.1.4). In the other cases mainly reversible 
kidney failure, cinchonism, lengthy auditory deficits and blindness were diagnosed in the 
patients (8). 
 
In the context of various case descriptions of quinine-related intravascular haemolysis, 
followed by tubular necrosis and acute kidney failure during pregnancy there are repeated 
comments that haemolytic anaemias following quinine administration were most frequently 
observed during early pregnancy and that there was a wide variation in the individually 
tolerated dose. For instance in one case a pregnant woman died after taking only 0.4 g 
quinine (split into two doses) (15, 39-42). Discussions focus on whether the elevated 
sensitivity of red blood cells to quinine-related haemolysis in early pregnancy can be 
attributed to the fact that factors which normally inhibit haemolysis may be reduced during 
pregnancy (42). 
 
Dannenberg et al. mentioned blindness, deafness and a wide range of physical anomalies as 
teratogenic effects with a suspected association to quinine administration. However no 
typical quinine malformation syndrome can be identified (8). Nishimura et al. (13) also refer 
to some of the cases analysed in (8). They sum up that after the oral ingestion of various 
quinine doses (from 1 tablet up to 30 g, normally 1-4 g total) during the first trimester of 
pregnancy (one exception) 21 cases of anomalies were described in 12 publications between 
1949 and 1967. In 10 cases they affected the CNS (including 6 cases of hydrocephalus), 8 
times the extremities (including 3 cases of dysmelia), 7 cases the face, 6 cases the heart, 5 
cases digestive organs, 3 cases the urogenital tract (e.g. one newborn baby who died after 
20 hours and whose mother had ingested 2.3 g quinine in the 6th week of pregnancy had no 
kidneys (8, 43)), 3 cases hernias with various localisations and one case vertebrae. In 
addition, Nishimura et al. quote two publications which reported on mentally retarded 
offspring in conjunction with quinine ingestion during pregnancy. Nishimura et al. comment 
that no clear conclusions on the teratogenicity of quinine as a medicament can be drawn as 
no systematic or epidemiological studies were available on human malformations induced 
through the therapeutic use of quinine. 
 
3.1.2.1.7 Interactions 
 
Quinine reinforces the effect of digoxin, digitoxin and muscle relaxants. In interaction with 
other cinchona alkaloids there may be a mutual amplification of effect. Quinine can suppress 
the biosynthesis of vitamin K dependent coagulation factors whereby the effect of 
anticoagulants can be increased. Quinine ingestion can also lead to elevated plasma levels 
of warfarin and related anticoagulants (2, 33) (cf. 3.1.2.3.2). As already mentioned, urine-
alkalising agents can delay quinine excretion thereby amplifying the toxic effect (1-3, 5, 6). 
 
3.1.2.1.8 Intoxications 
 
The fatal oral quinine dose for adults with a healthy heart is 5 to 10 g and 1 to 2 g (5) for 
children who are deemed to by hypersensitive to quinine. The ingestion of 2 g quinine is life-
threatening for adults with a heart complaint. Overdoses lead, among others, to severe 
central nervous disorders and cardiac complications. Death is caused by cardiac arrest or 
respiratory paralysis (3, 6). 
 
3.1.2.2 Cinchona bark in medicine 
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The monograph “Cinchona cortex (cinchona bark)” of Committee E of the former Federal 
Health Office (16) lists for a daily dose1 of 1 to 3 g drug the indications loss of appetite and 
dyspeptic disorders (referring to the effect of promoting gastric juice and saliva secretion), 
the contraindications pregnancy and hypersensitivity to cinchona alkaloids and the 
interactions amplification of the effect of anticoagulants. It indicates as adverse reactions 
sporadic hypersensitivity reactions and, on rare occasions, an elevated bleeding tendency as 
a consequence of thrombocytopenia. In these cases a doctor should be consulted 
immediately. Furthermore, it is pointed out that ingestion may lead to sensitisation to quinine 
and quinidine. 
 
Already in the commentary on the 9th edition of the German Pharmacopoeia (10) the use of 
the composed cinchona tincture Cinchonae tinctura composita is described as “no longer to 
be recommended” because of the risk of allergenicity. 
 
3.1.2.3 Quinine in foods 
 
3.1.2.3.1 Expert opinions of international bodies 
 
As far as the safe use of quinine in foods and, more particularly, in soft drinks is concerned, 
assessments are available from the Scientific Committee on Food (SCF) (17) from 1988 and 
the Joint FAO/WHO Expert Committee on Food Additives (JECFA) from 1990 (18) and 1993 
(19). They rely, amongst other things, on in vitro studies, animal experiments and human 
findings. Reference can only be made here to some excerpts and by way of summary of 
these data. For more detailed information please refer to the expert opinions mentioned in 
the references (17-19). In this context it should be pointed out that quinine or quinine salts 
are classified in the EU Register of Flavouring Substances (20, 21) as substances for priority 
assessment (22). 
 
In its assessment SCF comes to the following conclusions (17): 
 
The Committee is now assured that no adverse reproductive or teratological effects will result 
from the use of quinine in bitter soft drinks. 
 
The Committee has also been provided with information on actual and potential intakes of 
quinine from bitter soft drinks at a European level. The estimated actual intake in European 
countries is, on average, of the order of 0.26 mg /person /day, and for regular consumers of  
bitter drinks, it is unlikely that the mean daily intake will exceed 5 mg quinine/person/day. 
This information is reassuring for the Committee and it has noted that intake appears to be 
restricted to the adult population. 
 
Military jet-pilots consuming 105 mg quinine daily showed, under extremely strenuous 
conditions, mild adverse effects, but these effects are not considered relevant in the context 
of the use of quinine as a food additive. For human volunteers under normal conditions 120 
mg/person/day gave no effect. This should be considered in relation to the estimated 
maximum daily intake of 5 mg/person/day in Member States. 
 
Some individuals are hypersensitive to quinine, as occurs with other food components and 
food additives. These persons should be informed by the specific mention of the presence of 
quinine on the label. 
                                                
1  Based on a quinine level of 0.8-4% (5), a daily dose of 1 to 3 g cinchona bark in a drug corresponds to a daily dose of 
between 8 mg and 120 mg quinine, combined with other cinchona alkaloids. 
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The Committee sees no objection from a toxicological point of view to the continued use at 
present levels (up to max. 100 mg/l) of quinine in bitter drinks. 
 
The summary assessment by JECFA from 1990 states (18): 
 
COMMENTS 
 
Biochemical studies, short-term studies in rats, teratology studies in rats, and mutagenicity 
studies were reviewed. In these studies, no-effect levels ranged from 40 mg per kg bw per 
day to 100 mg per kg bw per day. Mutagenicity studies were negative. 
Varied complaints including headaches and transient visual problems were reported in 
human volunteer studies using doses of 100 mg of quinine hydrochloride per person per day. 
These findings were not confirmed in a second, controlled study using 120 mg per person 
per day. A third study showed electronystagmographic changes in stressed subjects for 
which a no effect level of 52.5 mg quinine per person per day was determined. 
The Committee concluded that a Temporary ADI could be established on the basis of the 
human data. In view of the fact that the toxicity of concern was acute and reversible in nature 
and that there is extensive experience of human consumption without reports of acute 
toxicity except very rarely in individuals with hypersensitivity, the Committee saw no need to 
require a margin of safety. 
 
EVALUATION 
 
Level causing no toxicological effect 
Rats:  40 mg quinine hydrochloride/kg bw/day 
Humans:  0.9 quinine mg/kg bw/day. 
 
Estimate of temporary acceptable daily intake 
0-0.9 mg quinine/kg bw/day. 
 
This was updated by the JECFA Opinion from 1993 (19) with the following wording: 
 
COMMENTS 
 
The Committee concluded that the data demonstrated a clear NOEL with respect to the 
ocular effects of 80 mg of anhydrous quinine hydrochloride per day, equivalent to 72 mg of 
quinine free base. No treatment-related effects on audition or clinical biochemical 
abnormalities were observed at doses up to 160 mg of anhydrous quinine hydrochloride per 
day. 
 
EVALUATION 
 
The previously established temporary ADI was withdrawn and, in the light of data on levels of 
use in beverages, the results of the consumption study and the additional data on humans, 
the Committee concluded that current use levels in soft drinks of up to 75 mg/l (as quinine 
base) were not of toxicological concern. However, the Committee noted that a small group of 
consumers shows an idiosyncratic hyper-reactivity to quinine, and recommended that the 
consumer should be informed by appropriate means of the presence of quinine in foods and 
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beverages in which it is used. The contribution of other uses of quinine in food and alcoholic 
beverages to daily intakes was considered to be negligible. 
 
This evaluation was again subject to change in the following way (44): 
At its present meeting, the Comittee re-assessed the toxicological information in the light of 
new data on levels of quinine in beverages. The Committee concluded that current levels of 
up to 100 mg/l (as quinine base) in soft drinks were not of toxicological concern. The 
contribution of other uses of quinine in food and alcoholic beverages to daily intakes was 
considered to be negligible. The Committee again noted that certain consumers showed 
idiosyncratic hyper-reactivity to quinine, and reiterated its recommendation that the consumer 
should be informed by appropriate means of the presence of quinine in foods and beverages 
in which it is used. A toxicological monograph was not prepared. The existing specifications 
for quinine hydrochloride and quinine sulfate were revised. 
 
The short-term, oral studies in rats mentioned in the JECFA Monograph published in 1990 
have since been published (23). Mainly because of the results of two 13-week studies, on the 
basis of which 40 and 60 mg quinine hydrochloride/kg bw/day were derived as the no effect 
level (NEL), the examiners stated that at high doses (100 and 200 mg/kg bw/day) quinine 
hydrochloride has a low-grade hepatotoxicity and that the kidney can be identified as a 
possible target organ (elevated plasma urea level combined with slightly elevated values of 
inorganic phosphorus, slightly elevated kidney weights in males, , dose-related clearly higher 
water consumption of pregnant mice at 100 and 200 mg/kg bw/day (see following description 
of the rat teratogenicity study). 
 
According to JECFA no long-term or carcinogenicity studies are available (18). 
 
In the SCF and JECFA assessments it was also considered which studies were available 
that permitted statements about possible reprotoxic and embryotoxic effects. The JECFA 
(18) assessment points out that reproduction studies are lacking. 
 
From the available animal teratology studies, JECFA (18) mentions a gavage study (23) 
(published in the meantime) in which four groups of 25 pregnant rats were administered oral 
doses of 0, 50, 100 or 200 mg quinine hydrochloride per kg bw/day from day 6 to day 15 of 
pregnancy. In accordance with the findings of the 13-week feed studies, the dams in the two 
upper dose groups showed lower body weight gains than the control animals. The clearly 
higher dose-related water consumption of the dams in the groups with 100 and 200 mg/kg 
bw/day is noticeable. The investigators discussed this in conjunction with the influenced 
parameters of the 13-week studies which affected kidney function (see above). However, in 
the case of the animals investigated there, no elevated drinking water consumption was 
observed. Litter and foetal weights (means) were significantly reduced in the highest dose 
group. There was a significant increase in the total of variants of the sternebrae (ossification 
centres in the sternum segments) and a slight increase in the 100 mg/kg bw/day dose group 
compared to controls. There are no differences in pregnancy data, total of resorptions, litter 
size, sex ratio or major malformations between dose groups. The number of visceral 
anomalies appeared to be elevated in the highest dose group compared with the other 
groups (not significantly). The authors concluded that the 100 mg/kg bw/day group showed 
no adverse effects on embryo or foetal development. 
 
In another rat study (24) published by Lapointe and Nosal two groups each consisting of 
5 dams were given either 0 or 0.25 mg/ml quinine in their drinking water, starting two weeks 
prior to gestation and continuing throughout gestation and lactation (approximately 40 mg/kg 
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bw/day). Pups from the quinine treated dams weighed significantly less at birth, had 
significantly delayed eye opening and teeth eruption, and one neonate each was observed 
with syndactylia in the right forelimb or anophthalmia of the right eye. Given the low numbers 
in the groups and other shortcomings, the results must be viewed as not completely reliable 
(18). 
 
Furthermore, unpublished teratogenicity studies on deoxyquinine, a degradation product of 
quinine which is formed through exposure to sunlight, were included by SCF and JECFA in 
the assessments (17, 18). In one study four groups each with 30 rats were dosed by oral 
gavage with either 0, 6.67; 20 or 60 mg/kg bw/day from day 6 to day 15 of gestation. 20 
animals in each group were killed and the foetuses examined. The development of the 
offspring was examined regarding the remaining 10 animals. The mean litter sizes in the 6.67 
and 60 mg/kg bw/day groups were reduced; this was attributed by the research scientists to 
pre-implantation losses not related to treatment. There were an increased percentage of 
foetuses with 14 ribs in the 60 mg/kg bw/day group. The investigators did not observe any 
treatment-related developmental effects (assessment of incisor eruption, pinna unfolding, 
eye opening, startle response, pupil reflex, surface righting reflex, air righting reflex). The 
authors concluded that there were no significant adverse treatment-related effects at the 
levels of deoxyquinine used in the study (17, 18). 
 
In another oral study (oral gavage) 4 groups of 15 rabbits were dosed by gavage with either 
0, 20, 40 or 80 mg/kg bw/day of deoxyquinine from day 6 to day 18 of gestation. In the high 
dose group 3 animals died shortly after treatment; the other animals showed reduced weight 
gain from day 10 to day 23 of gestation. The investigators did not observe any significant 
treatment-related developmental toxicity. In a prior orientational study weight loss, increased 
mortality, anorexia, behavioural changes, cramps and collapse were observed in parent 
animals at a dose of 135 mg/kg bw/day (17, 19). 
 
In the SCF assessment other teratogenicity studies on quinine are given as references 
without any further details (17). For instance the studies by Tanimura (12) revealed that after 
oral administration of doses of quinine hydrochloride of 20, 100 or 200 mg/kg bw/day to a 
total of 6 apes (macaca fuscata or macaca mulatta) from day 27 to day 29 of gestation, the 
only anomaly observed was a 13th rib in one foetus (20 mg/kg bw/day). Retroplacental 
haematomas and / or yellowish amniotic fluid in 2 out of the 6 treated animals (20 and 
100 mg/kg bw/day) were taken as possible signs of abortive effects. The publication by 
Tanimura lists the results of ten older teratogenicity studies in various species with 
differences concerning dose, treatment interval and mode of administration. The results of 
two studies do not point to any embryotoxicity or malformations whereas in the otherones 
degeneration of the auditory nerve and ganglion cochlear, mitochondrial changes and 
haemorrhagia in the cochlea as well as repeated CNS anomalies (like anencephaly and 
microcephaly), retarded growth and death in the uterus were noted. 
 
3.1.2.3.2 Case reports and individual opinions on quinine-containing foods 
 
Some scientific publications consider the problem of adverse reactions or drug interactions 
as a consequence of the consumption of quinine-containing soft drinks (25-34). Publications 
thematising the occurrence of visual and auditory disorders as well as headache following 
the consumption of quinine-containing tonic drinks and the derivation of the corresponding no 
observed adverse effect level (25-27) were discussed in more detail in the SCF and JECFA 
reports (17-19). From other publications we know that severe hypersensitivity reactions can 
sometimes be triggered by the consumption of quinine-containing soft drinks (e.g. one glass 
bitter lemon). There are reports, for instance, of thrombocytopenic purpura indicated as 
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“bitter lemon purpura” or haemolytic anaemias, which in some cases were complicated by 
kidney failure; in this conjunction disseminated intravasal coagulations were diagnosed (28-
31). 
 
For the present question a publication by Evans et al. (32) is particularly relevant. The 
authors reported about a neonate, which was described as jittery 24 hours after birth. These 
symptoms were still diagnosed on days 7 and 15, but not 2 months after birth. From the 24th 
week of pregnancy until birth in the 41st week of pregnancy, the mother had drunk 1,136 ml 
tonic water daily. This is equivalent to a daily quinine intake of 60 mg. During this time she 
had suffered twice from tinnitus. On the 7th day after birth maternal blood was tested negative 
for quinine, however quinine could be detected in the infant’s urine. The authors believe that 
quinine withdrawal caused the infant’s symptoms. They explain that quinine increases the 
refractory period of skeletal muscles and that the withdrawal of quinine had probably led to 
disinhibition of the skeletal muscles. 
 
Furthermore, cases have been published in which the quinine intake from larger amounts of 
tonic water led to the need to readjust anticoagulant treatment. For instance one patient’s 
condition had been kept stable for months by administering 6 mg warfarin/day when her daily 
warfarin requirements suddenly fell to 4 mg or below. The cause was determined to be the 
daily consumption of 1-1.5 l tonic water. Once she stopped drinking this, the warfarin dose 
had to be readjusted to its original level. In a second patient, it was suddenly necessary to 
reduce the daily warfarin dose from 4 mg to 2 mg whereby there were readjustment 
difficulties over a few days. Here, too, a high consumption of tonic water (more than 2 l daily) 
was determined to be the cause. Referring to a quinine level of 79 mg/l of the consumed soft 
beverages the author assumes a daily quinine intake of 80-180 mg by his patients (33). 
 
Regarding the relevant publications on the consumption of quinine-containing soft drinks (23, 
25, 26, 32, 33), Berglund (34) made the following comments in the journal “Toxicology”: 
 
It is unfortunate if the public is given the impression that drinks containing quinine are safe. 
Transient blurring of vision can be disastrous if experienced by air plane pilots or motor 
vehicle drivers. Interaction with warfarin and neonatal withdrawal jitteriness should be of 
concern. 
 
Finally, attention should be drawn to non-official information on the Internet in which the 
drinking of tonic water is recommended for pregnant women as a way of preventing or 
treating the onset of nocturnal leg cramps. Other websites, by contrast, advise against the 
consumption of tonic water during pregnancy because of its potential labour-inducing effects. 
 
3.1.2.3.3 Exposure to quinine-containing soft drinks 
 
According to SCF, which drew on information from UNESDA (Union of European Carbonated 
Beverages Associations in EU Countries), non-alcoholic tonic beverages have a maximum 
quinine content of 80 mg/l and bitter lemon drinks a maximum quinine content of 45 mg/l. 
Furthermore, some alcoholic aperitifs contain quinine (approximately 10 mg/l). However, the 
substance would not be used in other foods (17). 
 
Whereas the SCF report (17) had to refer to consumption data from older market studies 
(cf. 3.1.2.3.1), JECFA (19) quotes data from a more recent consumption study of consumers 
of quinine-containing soft drinks in the United Kingdom, France and Spain (Quinine 
Consumption Study, unpublished report, Cadbury Beverages Inc., 1991). According to this 
average quinine intake over 14 days was between 6.1 and 9.3 mg/person/day 
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(90th percentile); the maximum quinine intake on one individual day ranged from 
75 mg/person in France to 104.4 mg/person in the United Kingdom (based on a body weight 
of 60 kg maximum exposure values of 1.25 mg/kg bw/day and 1.74 mg/kg bw/day, 
respectively, are calculated). With a content of 80 mg quinine/l this would correspond to 
consumption between 940 and 1,300 ml of the beverage per person per day. This intake 
seems to be realistic in individual cases as quinine-containing soft drinks may be the main 
source of fluid to quench thirst and they are sold in comparatively large bottles (e.g. with the 
volume of 1 litre). This is confirmed by the case descriptions outlined above (cf. 3.1.2.3.2). 
 
Regarding the consumption of quinine-containing soft drinks by special risk groups, there are 
no known exposure data aside from one study from the United Kingdom mentioned in the 
SCF expert opinion (17). According to this study children up the age of 15 years account for 
1% of the total consumption of tonic and approximately 5% of the total consumption of bitter 
lemon drinks. 
 
As far as consumption during pregnancy is concerned, it can be assumed that women who 
drank quinine-containing soft drinks regularly and/or in larger amounts as thirst quenchers 
prior to pregnancy will continue to do this during pregnancy. Thus even pregnant women 
may have daily maximum exposures of around 100 mg/person/day. Also relevant for risk 
assessment is the possibility that women drink larger amounts of quinine-containing soft 
drinks during pregnancy than they did before by following unofficial advice e.g. to alleviate 
nocturnal leg cramps, overcome morning sickness or replace alcoholic beverages. 
 
3.1.3 Assessment and discussion 
 
3.1.3.1 Consumption during pregnancy 
 
In its assessment BfR focuses on whether quinine intake from soft drinks during pregnancy 
could result in adverse reactions for the maternal organism and / or offspring. As quinine-
containing soft drinks may also be consumed during pregnancy to quench thirst, BfR 
assumes daily maximum exposure of about100 mg quinine/person/day as a possible worse 
case scenario. Particularly with a view to pregnant women and their offspring, BfR believes 
that a risk assessment based on average daily exposures calculated from intakes over a 
longer period, is not justified as acute dose-response relationships should be analysed, too. 
Considering embryotoxicity short term exposure during a sensitive time span is relevant. .For 
quinine various reprotoxic effects have been described for humans and animals. Both 
regarding foetal as well as maternal parameters there are however major gaps in knowledge 
particularly about dose-response relationships and threshold doses. Hence, a definitive risk 
assessment is not possible on the basis of the data mentioned above. 
 
As far as embryotoxic (teratogenic) effects in animals (cf. 3.1.2.3.1) are concerned, a no 
observed adverse effect level (NOAEL) of 100 mg quinine hydrochloride/kg bw/day 
(equivalent to 82 mg quinine base/kg bw/day) was derived from a study in rats (23). This 
NOAEL only has a margin of factor 47 to the highest maximum daily exposure mentioned by 
JECFA of 104.4 mg quinine/person/day (equivalent to 1.74 mg quinine/kg bw/day) from 
quinine-containing soft drinks (cf. 3.1.2.3.3). This comparison implicates uncertainties as, 
contrary to what is normally required, no other embryotoxicity study with quinine in non-
rodents (aside from the rabbit study with deoxyquinine) confirms the findings from the above-
mentioned animal experiment. Furthermore, a second perinatal study in rats which is only 
reliable to a limited degree because of the inadequate test regimen (24) points to a lower 
NOAEL. In humans various teratogenic effects were linked to the ingestion of quinine as an 
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abortifacient normally in doses of total 1-4 g leading to a margin of around factor 10-40 to the 
above mentioned maximum daily quinine exposure from soft drinks (cf. 3.1.2.1.6). 
 
What is of particular relevance for this risk assessment is a case of withdrawal symptoms 
and related major (albeit seeming reversible) health impairments in a newborn baby whose 
mother had regularly consumed amounts of tonic water during pregnancy that corresponded 
to 60 mg quinine per day (3.1.2.3.2). Because of the easy placenta accessibility, the intake of 
only 60 mg quinine per day already leads to foetal quinine blood levels which effect the foetal 
organism (i.e. probable elevation of the refractory time of the skeletal muscles) since there 
could not be any withdrawal symptoms if this was not the case. These facts also highlight 
deficits concerning present knowledge of quinine induced reprotoxicity. Aside from animal 
multi-generation studies, there are no reliable animal studies on perinatal or postnatal 
development either, in which exposure is not restricted (like in the above mentioned study by 
Colley et al. (23) or in the teratogenicity studies with deoxyquinine in rats and rabbits (cf. 
3.1.2.3.1)) to the short phase of organogenesis but rather encompasses the entire process 
from foetal development over birth until the end of lactation, and which focus more 
particularly on prenatally induced functional abnormalities and behavioural changes in the 
post-natal course of development, too. There is no information on the threshold dose, 
possible sequelae or later developmental disorders concerning the effect of quinine on the 
foetus which led to the withdrawal symptoms. Beside this, there is also a need for research 
with respect to indications of quinine accumulation in foetal tissue which can be derived from 
old studies (cf. 3.1.2.1.3). 
 
There are no sufficient data on dose-response relationships or threshold doses either 
concerning the oxytocic action of quinine which carries the risk of miscarriage or premature 
birth with all the associated risks. In the past doses of between 300 mg and 500 mg of 
quinine were administered twice daily (orally) to induce labour. However, this effect has not 
been confirmed (cf. 3.1.2.1.2). Because of the oxytocic effect of quinine, pregnancy is a 
contraindication for the treatment of nocturnalleg cramps with this agent(cf. 3.1.2.1.1 and 
3.1.2.1.5). The dose used here corresponds to 166 mg free quinine base and is, therefore, 
only 1.6 times higher than the above-mentioned maximum daily intake of 104.4 mg quinine 
from bitter soft drinks. In the monograph of Committee E of the former Federal Health Office 
(16) pregnancy is also indicated as a contraindication for cinchona bark, the use of which as 
a medicine leads to quinine intakes which correspond to the quinine amounts consumed in 
bitter soft drinks (cf. 3.1.2.2). On the other hand, in conjunction with considerations whether 
severe cases of malaria should be treated with quinine during pregnancy, the oxytocin-like 
action of corresponding quinine doses in the third trimester of pregnancy is challenged (cf. 
3.1.2.1.6). In this context other, unconfirmed indications of abortive effects in monkey trials at 
20 and 100 mg/kg bw/day should be mentioned. 
 
Another maternal effect of quinine, for which there is no known threshold dose, is the 
induction of hyperinsulinaemia and hypoglycaemia which were observed in the course of 
malaria treatment in the last third of pregnancy (cf. 3.1.2.1.6). Furthermore, it is known, 
particularly from the use of quinine as an abortifacient, that in early pregnancy quinine may 
trigger acute haemolytic anaemias as hypersensitivity reactions which frequently prove fatal. 
In one case this happened after ingesting only 0.4 g quinine (cf. 3.1.2.1.4 and 3.1.2.1.6). 
There are no known statistics about the scale and severity of hypersensitivity and other 
intolerance reactions during pregnancy following the consumption of quinine-containing soft 
drinks. These gaps in knowledge make risk assessment more difficult, too. 
 
It has already been mentioned that, in the case of quinine from bitter soft drinks, amounts of 
an agent may be ingested that may have possible pharmacological effects and that are only 
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slightly lower than therapeutic doses (by a factor of 1.6). Otherwise this exceptional situation 
is only accepted in the food sector for certain central nervous stimulants (e.g. coffee) or 
depressants (alcoholic beverages). Not least the unofficial Internet recommendations to take 
tonic water for nocturnal leg cramps demonstrate the special position of quinine-containing 
bitter soft drinks. They show that the risk-prevention measures valid in the pharmaceutical 
sector are also relevant for the food sector. Here it should be taken into account that in the 
food sector there is neither medical advice or monitoring ; nor are any comprehensive 
dosage instructions or risk information provided. Finally, attention is drawn to one unclear 
aspect of quinine accumulation: the findings of a meta-analysis of the efficacy of leg cramp 
treatment point to the accumulation of repeated quinine administrations. However, this 
contradicts other pharmacokinetic information (cf. 3.1.2.1.1 and 3.1.2.1.3). 
 
Based on the data currently available and for the purposes of preventive health protection, 
BfR advises against consuming quinine-containing beverages during pregnancy. This 
recommendation is made on the basis of the existing contraindication during pregnancy for 
the administration of quinine-containing medicine for the treatment of nocturnal leg cramps 
and of cinchona bark containing pharmaceuticals. This recommendation not only reflects the 
numerous gaps in knowledge and low safety margins from exposure doses to NOAELand  
toxic or pharmacological doses respectively, but also the report on the health disorders of a 
newborn baby sustained after regular daily tonic water consumption by its mother (intake of 
60 mg quinine/day) during her pregnancy (cf. 3.1.2.3.2). Furthermore, this recommendation 
upholds the principle that health protection in the food sector should at least be on a par with 
risk reduction measures in the pharmaceutical sector whereby pregnant women, unborn 
babies and infants are to be deemed to be groups requiring special protection. 
 
3.1.3.2 Consumption by other groups of people 
 
Based on the general comments in Chapter 3.1.3.1.1 it is recommended that besides 
pregnant women, all those groups of individuals refrain from consuming quinine-containing 
soft drinks for whom the intake of quinine for the treatment of nocturnal leg cramps or of 
cinchona bark or its pharmaceutical preparations are contraindicated (3, 16). This applies to 
people who suffer from tinnitus, pre-existing damage to the optic nerve, glucose-6-
phosphate-dehydrogenase deficiency (symptoms: haemolytic anaemia), myasthenia gravis 
or hypersensitivity to quinine or cinchona alkaloids (cf. 3.1.2.1.5, 3.1.2.2). People with 
cardiac arrythmia (cf. 3.1.2.1.5) or who take medicine that interacts with quinine (cf. 
3.1.2.1.7, 3.1.2.2), should only drink quinine-containing soft drinks after consulting their 
doctors. This applies in particular to anticoagulant treatment as there have been reports of 
cases in which the dose of the anticoagulant preparation had to be reduced after elevated 
consumption of tonic water (3.1.2.3.2). For motor vehicle drivers, the mention of possible 
visual disturbances after consuming larger amounts of quinine-containing bitter beverages is 
relevant (cf. 3.1.2.3.2).  
 
Whether the recommendation to reduce the consumption of bitter soft drinks should also be 
made for breastfeeding women and children – according to the study from the United 
Kingdom quoted by SCF the latter account for 1 % of total consumption of tonic beverages 
and 5 % of total consumption of bitter lemon beverages – cannot be assessed on the basis 
of the knowledge currently available. There are no corresponding studies to answer this 
question, particularly about reproduction toxicology (3.1.2.3.1, 3.1.3.1.1). Furthermore, it has 
not yet been determined whether older people, too, are at higher risk as is mentioned in the 
literature in conjunction with the treatment of leg cramps (9) (3.1.2.1.1). 
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3.2 Management framework/measures 
 
3.2.1 Special measures 
 
The comments in Sections 3.1.3.1 and 3.1.3.2 indicate that the consumption of quinine-
containing beverages for various groups of consumers is linked to a risk. For that reason BfR 
believes measures are needed to inform those concerned in an appropriate manner. 
Warnings on labels are, in principle, the preferred option. Given the amount of information to 
be communicated, it is not easy to convert this into practice. Risk groups requiring medical 
care for their disease could be given detailed additional information during their medical 
consultation and treatment. 
 
Besides informing specific risk groups BfR also believes it is necessary to raise awareness 
amongst all consumers of quinine-containing soft drinks. They should be informed about the 
symptoms of cinchonism and quinine hypersensitivity (in particular neurotoxic effects like 
tinnitus, visual disorders, confusion; signs of thrombocytopenic purpura, for instance skin 
bleeding, haematomas). Furthermore, they should be advised to immediately stop ingesting 
quinine and consult a doctor if these symptoms occur. 
 
BfR recommends updating the SCF assessment from 1988 and proposes a coordinated EU-
wide approach for consumer information and future research. 
 
Based on this opinion BfR will conduct a survey amongst the German Poison Information 
and Treatment Centres to ascertain whether there have been reports of intolerance reactions 
and interactions with medicinal treatment as a consequence of the consumption of quinine-
containing soft drinks. Furthermore BfR will ask the Federal Institute for Drugs and Medical 
Devices (BfArM) for information on relevant reports of adverse reactions and the submission 
of previously unknown results. 
 
3.2.2 General measures 
 
The situation described above once again reveals that the the lacking of a systematic 
recording of adverse reactions in the food sector considerably impedes the assessment of 
existing risks and, by extension, their eradication. It can be assumed that in many cases 
adverse reactions have not been notified whereby it is difficult to estimate the real number of 
unreported cases. For that reason BfR supports the setting up of a central body to record 
and systematically document adverse reactions observed in conjunction with the 
consumption of foods (cf. on this subject the Health Assessment of Energy Drinks (BgVV 
Expert Opinion, 18 March 2002:  
http://www.bfr.bund.de/cm/208/gesundheitliche_bewertung_von_energydrinks.pdf)). 
 
The example of quinine-containing bitter drinks reveals that in certain cases (for specific 
foods and their components for certain risk groups) additional consumer information which 
extends beyond the information content of a label and is provided by an official source would 
be useful in order to minimise health risks. One option could be to give a contact address on 
the food label. Besides the telephone number and address, a website address could be 
presented where information prepared specifically for consumers could be obtained. This 
website could help consumers to orientate themselves in view of the diverse, often 
contradictory, information available on the Internet. 
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